EGFR+ Lung Cancer

Neoadjuvant osimertinib is effective and feasible for use as treatment for patients with stage II-IIIB EGFR-mutant lung adenocarcinoma, according to interim analysis results of the NEOS study.

In a retrospective analysis of patients with advanced non–small cell lung cancer and EGFR mutations treated with osimertinib, investigators found that body mass index of 25 kg/mq2 or more had a negative impact on survival outcomes.

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the current standard of care for EGFR exon 20 insertion-mutated lung cancer.

Joshua K. Sabari, MD, reviews the therapies available to treat patients with EGFR exon 20-positive non–small cell lung cancer.

New data from the phase 3 IMPACT trial shows the advantages and shortcomings of gefitinib in patients with EGFR-mutant non-small cell lung cancer.

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.

Treatment with aumolertinib led to improved progression free survival and duration of response in patients with advanced non-small cell lung caner with epidermal growth factor receptor, compared with gefitinib.

treatment with patritumab deruxtecan induced clinically meaningful, durable efficacy in heavily pretreated patients with EGFR-mutated non–small cell lung cancer who were resistant to EGFR tyrosine kinase inhibitors.

Amivantamab in combination with lazertinib led to responses in more than a third of patients with EGFR-mutant non–small cell lung cancer who had progressed on treatment with osimertinib but had not received chemotherapy.

Mobocertinib, elicited rapid, deep, and durable responses and demonstrated a tolerable safety profile in patients with platinum-pretreated EGFR exon 20 insertion–positive metastatic non–small cell lung cancer in a phase 1/2 study.

The FDA has granted approval to amivantamab-vmjw for the frontline treatment of adult patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.

In an interview with Targeted Oncology, Xiuning Le, MD, PhD, discuss the findings from cohort 5 of the ZENITH20 study including the strategy of splitting the dose in half to reduce adverse events associated with poziotinib.

Xiuning Le, MD, PhD, discusses the reasoning behind splitting the dose of poziotinib dose in order to reduce adverse effects and improve efficacy for the treatment of EGFR- or HER2 exon 20–positive non–small cell lung cancer.

Karen L. Reckamp, discussed the progression-free survival benefit achieved with ramucirumab in patients with EGFR-positive lung cancer.

Regular dose osimertinib demonstrated limited clinical activity in patients with non-small cell lung cancer harboring an EGFR exon 20 insertion who were treated in a phase 1/2 study.

The combination of oleclumab and osimertinib was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer with an EGFR mutation after progression on an EGFR tyrosine kinase inhibitor.

The FDA has granted a priority review to mobocertinib as a treatment for adult patients with EGFR exon 20 insertion–mutant metastatic non–small cell lung cancer, as detected by an FDA-approved test, and who have received prior platinum-based chemotherapy.

More than half of patients with T790M-positive non-small cell lung cancer had a response to the third generation EGFR TKI D-0316 in a phase 2 study.

Xiuning Le, MD, PhD, discusses the limited treatment options available for patients with non–small cell lung cancer and an EGFR exon 20 mutation.

According to a retrospective analysis presented during the 2021 European Lung Cancer Congress, earlier diagnosis and biomarker testing should be more widely implemented to identify patients with EGFR-positive non–small lung cancer who may benefit for EGFR inhibition.

Integrating afatinib into standard-of-care chemoradiation with or without surgery demonstrated encouraging efficacy, feasibility, and safety results in patients with stage III EGFR-mutation positive non–small cell lung cancer.

Neratinib demonstrated single-agent efficacy with significant response and survival rates in tyrosine kinase inhibitor-refractory patients with non– small cell lung cancer whose tumors harbor EGFR exon 18 mutations.

Leora Horn, MD, discusses how real-world data of mobocertinib as treatment of refractory EGFR-positive non–small cell lung cancer and other real-world studies can impact the treatment paradigm.

In an interview with Targeted Oncology, Julia K. Rotow, MD, a medical oncologist at the Dana-Farber Cancer institute, discuses the results of the study of gefitinib in combination with osimertinib as frontline treatment of patients with EGFR-mutated NSCLC.

In with EGFR-mutant non–small cell lung cancer and brain metastases, oral osimertinib achieved rapid, high, and uniform brain exposure which was followed reduction in total brain metastases volume, according to results from the phase 1 ODIN-BM study.

n patients with resectable, stage II-IIIB non–small cell lung cancer whose tumors harbor EGFR mutations, neoadjuvant osimertinib will be administered as a single agent or in combination with platinum-based chemotherapy compared with chemotherapy alone in the NeoADAURA trial

The combination of osimertinib and selpercatinib was found to be an active regimen in patients with EGFR-positive non–small cell lung cancer with acquired RET fusions.

Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.

Patient-reported outcomes from the phase 3 ADAURA trial showed that adjuvant osimertinib maintained health-related quality of life compared with placebo in patients with EGFR-positive non–small cell lung cancer.

Mobocertinib induced responses among patients with metastatic non–small cell lung cancer who have EGFR exon 20 insertion mutations and previously treated disease, according to findings from a phase 1/2 trial.